Science Hub
Welcome to Novo Nordisk Science Hub
The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.
The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.
Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.
By accessing this website you accept this legal notice and expressly confirm your status as a healthcare professional.
Richard M. Bergenstal is an endocrinologist and Executive Director of the International Diabetes Center at HealthPartners Institute, Minneapolis, MN, USA. He is Clinical Professor in the Department of Medicine at the University of Minnesota, Minneapolis and served as President, Science & Medicine of the American Diabetes Association (ADA) in 2010. In 2007, Prof. Bergenstal was named the ADA’s Outstanding Physician-Clinician of the Year and in 2010 was awarded the Banting Medal for Service. He received his MD and endocrine training from the University of Chicago, Chicago, IL, USA, where he was an Assistant Professor of Medicine before joining the International Diabetes Center in 1983.
His clinical research has focused on glucose control and diabetes complications and advanced technology, including continuous glucose monitoring and automated insulin delivery systems, and he has served as a Principal Investigator of five National Institutes of Health trials.
Prof. Bergenstal’s clinical efforts are directed towards improving systems of care for patients with diabetes by translating new research findings into practice. He teaches on the importance of patient‐centred team care, has been listed in Best Doctors in America since it began in 1992, and has published more than 300 peer-reviewed scientific articles.
